{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:47:37Z","timestamp":1780760857582,"version":"3.54.1"},"reference-count":116,"publisher":"Bentham Science Publishers Ltd.","issue":"14","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>COVID-19, an extremely transmissible and pathogenic viral disease, triggered a global\npandemic that claimed lives worldwide. To date, there is no clear and fully effective treatment for\nCOVID-19 disease. Nevertheless, the urgency to discover treatments that can turn the tide has led\nto the development of a variety of preclinical drugs that are potential candidates for probative results.\nAlthough most of these supplementary drugs are constantly being tested in clinical trials\nagainst COVID-19, recognized organizations have aimed to outline the prospects in which their\nuse could be considered. A narrative assessment of current articles on COVID-19 disease and its\ntherapeutic regulation was performed. This review outlines the use of various potential treatments\nagainst SARS-CoV-2, categorized as fusion inhibitors, protease inhibitors, and RNA-dependent\nRNA polymerase inhibitors, which include antiviral drugs such as Umifenovir, Baricitinib, Camostatmesylate,\nNafamostatmesylate, Kaletra, Paxlovide, Darunavir, Atazanavir, Remdesivir, Molnupiravir,\nFavipiravir, and Ribavirin. To understand the virology of SARS-CoV-2, potential therapeutic\napproaches for the treatment of COVID-19 disease, synthetic methods of potent drug candidates,\nand their mechanisms of action have been addressed in this review. It intends to help\nreaders approach the accessible statistics on the helpful treatment strategies for COVID-19 disease\nand to serve as a valuable resource for future research in this area.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201024666230302113110","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:57:57Z","timestamp":1677758277000},"page":"1727-1739","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2:\nA Review"],"prefix":"10.2174","volume":"24","author":[{"given":"Yashumati","family":"Ratan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 304022, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Rajput","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 304022, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical\nSciences, Mohanlal Sukhadia University, Udaipur, 313001, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Kumar","family":"Mishra","sequence":"additional","affiliation":[{"name":"Indore Institute of Pharmacy, Rau,\nIndore, 453331, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh Kumar","family":"Gautam","sequence":"additional","affiliation":[{"name":"Indore Institute of Pharmacy, Rau,\nIndore, 453331, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Pareek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 304022, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/jammr\/2020\/v32i430393","volume":"32","author":"Ahmed S.S.","year":"2020","unstructured":"Ahmed S.S.; The coronavirus disease 2019 (COVID-19): A review. J Adv Med Med Res 2020,32(4),1-9","journal-title":"J Adv Med Med Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.26355\/eurrev_202003_20712","volume":"24","author":"Lou J.","year":"2020","unstructured":"Lou J.; Tian S.J.; Niu S.M.; Kang X.Q.; Lian H.X.; Zhang L.X.; Zhang J.J.; Coronavirus disease 2019: A bibliometric analysis and review. Eur Rev Med Pharmacol Sci 2020,24(6),3411-3421","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=3","year":"2020","unstructured":"Coronavirus disease - 2019 (COVID-19). WHO situation report-94 Available from: 2020","journal-title":"WHO situation report-94"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s10096-020-03899-4","volume":"39","author":"Wang H.","year":"2020","unstructured":"Wang H.; Li X.; Li T.; Zhang S.; Wang L.; Wu X.; Liu J.; The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020,39(9),1629-1635","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=5","year":"2020","unstructured":"European Centre for Disease Prevention and Control. Cluster of Pneumonia Cases Caused by a Novel Coronavirus Wuhan, China.  Available from: 2020"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jiph.2020.07.011","volume":"13","author":"Bchetnia M.","year":"2020","unstructured":"Bchetnia M.; Girard C.; Duchaine C.; Laprise C.; The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health 2020,13(11),1601-1610","journal-title":"J Infect Public Health"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"Lu R.","year":"2020","unstructured":"Lu R.; Zhao X.; Li J.; Niu P.; Yang B.; Wu H.; Wang W.; Song H.; Huang B.; Zhu N.; Bi Y.; Ma X.; Zhan F.; Wang L.; Hu T.; Zhou H.; Hu Z.; Zhou W.; Zhao L.; Chen J.; Meng Y.; Wang J.; Lin Y.; Yuan J.; Xie Z.; Ma J.; Liu W.J.; Wang D.; Xu W.; Holmes E.C.; Gao G.F.; Wu G.; Chen W.; Shi W.; Tan W.; Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020,395(10224),565-574","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1101\/2020.02.07.937862","volume":"5","author":"Gorbalenya A.E.","year":"2020","unstructured":"Gorbalenya A.E.; Baker S.C.; Baric R.S.; De Groot R.J.; Drosten C.; Gulyaeva A.A.; Haagmans B.L.; Lauber C.; Leontovich A.M.; Severe acute respiratory syndrome-related coronavirus: the species and its viruses \u2013 a statement of the coronavirus study group. Biorxiv 2020,5(4),536-544","journal-title":"Biorxiv"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","volume":"26","author":"Petrosillo N.","year":"2020","unstructured":"Petrosillo N.; Viceconte G.; Ergonul O.; Ippolito G.; Petersen E.; COVID-19, SARS and MERS: Are they closely related? Clin Microbiol Infect 2020,26(6),729-734","journal-title":"Clin Microbiol Infect"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.46234\/ccdcw2020.032","volume":"2","year":"2020","unstructured":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. China CDC Weekly China CDC Weekly, C2020,2(8),113-122","journal-title":"China CDC Weekly"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/13543784.2021.1847270","volume":"30","author":"Malinis M.","year":"2021","unstructured":"Malinis M.; McManus D.; Davis M.; Topal J.; An overview on the use of antivirals for the treatment of patients with COVID-19 disease. Expert Opin Investig Drugs 2021,30(1),45-59","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cmdc.202000223","volume":"15","author":"Ghosh A.K.","year":"2020","unstructured":"Ghosh A.K.; Brindisi M.; Shahabi D.; Chapman M.E.; Mesecar A.D.; Drug development and medicinal chemistry efforts toward SARS-coronavirus and covid-19 therapeutics. ChemMedChem 2020,15(11),907-932","journal-title":"ChemMedChem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kr\u00fcger N.; Herrler T.; Erichsen S.; Schiergens T.S.; Herrler G.; Wu N.H.; Nitsche A.; M\u00fcller M.A.; Drosten C.; P\u00f6hlmann S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280","journal-title":"Cell"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jmv.25726","volume":"92","author":"Liu Z.","year":"2020","unstructured":"Liu Z.; Xiao X.; Wei X.; Li J.; Yang J.; Tan H.; Zhu J.; Zhang Q.; Wu J.; Liu L.; Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS\u2010CoV\u20102. J Med Virol 2020,92(6),595-601","journal-title":"J Med Virol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"Walls A.C.","year":"2020","unstructured":"Walls A.C.; Park Y.J.; Tortorici M.A.; Wall A.; McGuire A.T.; Veesler D.; Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020,181(2),281-292.e6","journal-title":"Cell"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/eurheartj\/ehaa396","volume":"41","author":"Guo Y.R.","year":"2020","unstructured":"Guo Y.R.; Cao Q.D.; Hong Z.S.; Tan Y.Y.; Chen D.; Jin H.J.; Tan K.S.; Wang D.Y.; Yan Y.; The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak \u2013 an update on the status. Eur Heart J 2020,41(22),2124-2125","journal-title":"Eur Heart J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1586\/14760584.2014.912134","volume":"13","author":"Zhang N.","year":"2014","unstructured":"Zhang N.; Jiang S.; Du L.; Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 2014,13(6),761-774","journal-title":"Expert Rev Vaccines"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.micinf.2020.01.003","volume":"22","author":"Yu F.","year":"2020","unstructured":"Yu F.; Du L.; Ojcius D.M.; Pan C.; Jiang S.; Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect 2020,22(2),74-79","journal-title":"Microbes Infect"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","volume":"17","author":"Xia S.","year":"2020","unstructured":"Xia S.; Zhu Y.; Liu M.; Lan Q.; Xu W.; Wu Y.; Ying T.; Liu S.; Shi Z.; Jiang S.; Lu L.; Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 2020,17(7),765-767","journal-title":"Cell Mol Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"Blaising J.","year":"2014","unstructured":"Blaising J.; Polyak S.J.; P\u00e9cheur E.I.; Arbidol as a broad-spectrum antiviral: An update. Antiviral Res 2014,107(1),84-94","journal-title":"Antiviral Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"Boriskin Y.","year":"2008","unstructured":"Boriskin Y.; Leneva I.; P\u00e9cheur E.I.; Polyak S.; Arbidol: A broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008,15(10),997-1005","journal-title":"Curr Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00063198-200405000-00009","volume":"10","author":"Brooks M.J.","year":"2004","unstructured":"Brooks M.J.; Sasadeusz J.J.; Tannock G.A.; Antiviral chemotherapeutic agents against respiratory viruses. Curr Opin Pulm Med 2004,10(3),197-203","journal-title":"Curr Opin Pulm Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","volume":"167","author":"Beigel J.H.","year":"2019","unstructured":"Beigel J.H.; Nam H.H.; Adams P.L.; Krafft A.; Ince W.L.; El-Kamary S.S.; Sims A.C.; Advances in respiratory virus therapeutics \u2013 A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 2019,167,45-67","journal-title":"Antiviral Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3949\/ccjm.87a.ccc030","author":"Srinivas P.","year":"2020","unstructured":"Srinivas P.; Sacha G.L.; Koval C.; Antivirals for COVID-19. Cleve Clin J Med 2020,1-5","journal-title":"Cleve Clin J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/jmv.25707","volume":"92","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Liu Y.; Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020,92(5),479-490","journal-title":"J Med Virol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF00772858","volume":"27","author":"Trofimov F.A.","year":"1993","unstructured":"Trofimov F.A.; Tsyshkova N.G.; Zotova S.A.; Grinev A.N.; Synthesis of a new antiviral agent, arbidole. Pharm Chem J 1993,27(1),75-76","journal-title":"Pharm Chem J"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","volume":"323","author":"Sanders J.M.","year":"2020","unstructured":"Sanders J.M.; Monogue M.L.; Jodlowski T.Z.; Cutrell J.B.; Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020,323(18),1824-1836","journal-title":"JAMA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1021\/jp102619w","volume":"114","author":"Villala\u00edn J.","year":"2010","unstructured":"Villala\u00edn J.; Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes. J Phys Chem B 2010,114(25),8544-8554","journal-title":"J Phys Chem B"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ph12010037","volume":"12","author":"Mayence A.","year":"2019","unstructured":"Mayence A.; Vanden E.J.; Baricitinib A.; 2018 novel FDA-approved small molecule inhibiting Janus kinases. Pharmaceuticals 2019,12(1),37","journal-title":"Pharmaceuticals"},{"key":"ref=30","year":"2018","unstructured":"FDA approves OLUMIANT\u00ae (Baricitinib) 2-mg tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis PRNewswire Eli Lilly and CompanyAvailable from: 2018","journal-title":"FDA approves OLUMIANT\u00ae (Baricitinib) 2-mg tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis PRNewswire"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"Richardson P.","year":"2020","unstructured":"Richardson P.; Griffin I.; Tucker C.; Smith D.; Oechsle O.; Phelan A.; Rawling M.; Savory E.; Stebbing J.; Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020,395(10223),e30-e31","journal-title":"Lancet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"Kalil A.C.","year":"2021","unstructured":"Kalil A.C.; Patterson T.F.; Mehta A.K.; Tomashek K.M.; Wolfe C.R.; Ghazaryan V.; Marconi V.C.; Ruiz-Palacios G.M.; Hsieh L.; Kline S.; Tapson V.; Iovine N.M.; Jain M.K.; Sweeney D.A.; El Sahly H.M.; Branche A.R.; Regalado Pineda J.; Lye D.C.; Sandkovsky U.; Luetkemeyer A.F.; Cohen S.H.; Finberg R.W.; Jackson P.E.H.; Taiwo B.; Paules C.I.; Arguinchona H.; Erdmann N.; Ahuja N.; Frank M.; Oh M.; Kim E.S.; Tan S.Y.; Mularski R.A.; Nielsen H.; Ponce P.O.; Taylor B.S.; Larson L.; Rouphael N.G.; Saklawi Y.; Cantos V.D.; Ko E.R.; Engemann J.J.; Amin A.N.; Watanabe M.; Billings J.; Elie M.C.; Davey R.T.; Burgess T.H.; Ferreira J.; Green M.; Makowski M.; Cardoso A.; de Bono S.; Bonnett T.; Proschan M.; Deye G.A.; Dempsey W.; Nayak S.U.; Dodd L.E.; Beigel J.H.; Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2021,384(9),795-807","journal-title":"N Engl J Med"},{"key":"ref=33","year":"2020","unstructured":"Baricitinib receives emergency use authorization from the FDA for the treatment of hospitalized patients with COVID-19 PRNewswire Eli Lilly and CompanyAvailable from: 2020","journal-title":"Baricitinib receives emergency use authorization from the FDA for the treatment of hospitalized patients with COVID-19 PRNewswire"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","volume":"81","author":"Cantini F.","year":"2020","unstructured":"Cantini F.; Niccoli L.; Nannini C.; Matarrese D.; Di Natale M.E.; Lotti P.; Aquilini D.; Landini G.; Cimolato B.; Di Pietro M.A.; Trezzi M.; Stobbione P.; Frausini G.; Navarra A.; Nicastri E.; Sotgiu G.; Goletti D.; Retrospective, multicentre study on the impact of baricitinib in COVID-19 moderate pneumonia. J Infect 2020,81(4),647-679","journal-title":"J Infect"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","volume":"81","author":"Cantini F.","year":"2020","unstructured":"Cantini F.; Niccoli L.; Matarrese D.; Nicastri E.; Stobbione P.; Goletti D.; Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020,81(2),318-356","journal-title":"J Infect"},{"key":"ref=36","author":"Rodgers J.","year":"2007","unstructured":"Rodgers J.; Shepard S.; Maduskuie T.; Wang H.; Falahatpisheh N.; Rafalski M.; Arvanitis A.; Storace L.; Jalluri R.; Fridman J.; Heteroarylsubstituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as Janus kinase inhibitors. 2007"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3184\/174751916X14569294811333","volume":"40","author":"Xu J.","year":"2016","unstructured":"Xu J.; Cai J.; Chen J.; Zong X.; Wu X.; Ji M.; Wang P.; An efficient synthesis of baricitinib. J Chem Res 2016,40(4),205-208","journal-title":"J Chem Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s11739-020-02345-9","volume":"15","author":"Uno Y.","year":"2020","unstructured":"Uno Y.; Camostat mesilate therapy for COVID-19. Intern Emerg Med 2020,15(8),1577-1578","journal-title":"Intern Emerg Med"},{"key":"ref=39","unstructured":"FOIPAN\u00ae Tablets 100 mg. Available from:"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/bcpt.13533","volume":"128","author":"Breining P.","year":"2021","unstructured":"Breining P.; Fr\u00f8lund A.L.; H\u00f8jen J.F.; Gunst J.D.; Staerke N.B.; Saedder E.; Cases-Thomas M.; Little P.; Nielsen L.P.; S\u00f8gaard O.S.; Kjolby M.; Camostat mesylate against SARS\u2010CoV\u20102 and COVID\u201019\u2014Rationale, dosing and safety. Basic Clin Pharmacol Toxicol 2021,128(2),204-212","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=41","year":"2020","unstructured":"The impact of camostat mesilate on COVID-19 infection. Clinicaltrials. gov. Available from: 2020"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1021\/acs.oprd.0c00233","volume":"24","author":"De Savi C.","year":"2020","unstructured":"De Savi C.; Hughes D.L.; Kvaerno L.; Quest for a COVID-19 cure by repurposing small-molecule drugs: mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org Process Res Dev 2020,24(6),940-976","journal-title":"Org Process Res Dev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","volume":"65","author":"Hoffmann M.","year":"2021","unstructured":"Hoffmann M.; Hofmann-Winkler H.; Smith J.C.; Kr\u00fcger N.; Arora P.; S\u00f8rensen L.K.; S\u00f8gaard O.S.; Hasselstr\u00f8m J.B.; Winkler M.; Hempel T.; Raich L.; Olsson S.; Danov O.; Jonigk D.; Yamazoe T.; Yamatsuta K.; Mizuno H.; Ludwig S.; No\u00e9 F.; Kjolby M.; Braun A.; Sheltzer J.M.; P\u00f6hlmann S.; Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine 2021,65,103255","journal-title":"EBioMedicine"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3389\/fonc.2019.00852","volume":"9","author":"Chen X.","year":"2019","unstructured":"Chen X.; Xu Z.; Zeng S.; Wang X.; Liu W.; Qian L.; Wei J.; Yang X.; Shen Q.; Gong Z.; Yan Y.; The molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications. Front Oncol 2019,9(9),852","journal-title":"Front Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0005-2744(81)90023-1","volume":"661","author":"Fujii S.","year":"1981","unstructured":"Fujii S.; Hitomi Y.; New synthetic inhibitors of C1r, C1 esterase thrombin, plasmin, kallikrein and trypsin. Biochimica et Biophysica Acta (BBA) - Enzymology 1981,661(2),342-345","journal-title":"Biochimica et Biophysica Acta (BBA) - Enzymology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Schroeder S.; Kleine-Weber H.; M\u00fcller M.A.; Drosten C.; P\u00f6hlmann S.; Nafamostatmesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother 2020,64(6),e00754-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1254\/jjp.35.203","volume":"35","author":"Aoyama T.","year":"1984","unstructured":"Aoyama T.; Ino Y.; Ozeki M.; Oda M.; Sato T.; Koshiyama Y.; Suzuki S.; Fujita M.; Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984,35(3),203-227","journal-title":"Jpn J Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/jth.14858","volume":"18","author":"Asakura H.","year":"2020","unstructured":"Asakura H.; Ogawa H.; Potential of heparin and nafamostat combination therapy for COVID\u201019. J Thromb Haemost 2020,18(6),1521-1522","journal-title":"J Thromb Haemost"},{"key":"ref=49","year":"2020","unstructured":"Gyeongsang National University Hospital Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia Available from: 2020","journal-title":"Gyeongsang National University Hospital"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1527-3466.1995.tb00213.x","volume":"13","author":"Okajima K.","year":"1995","unstructured":"Okajima K.; Uchiba M.; Murakami K.; Nafamostat mesilate. Cardiovasc Drug Rev 1995,13(1),51-65","journal-title":"Cardiovasc Drug Rev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.krcp.2015.10.003","volume":"35","author":"Kim H.S.","year":"2016","unstructured":"Kim H.S.; Lee K.E.; Oh J.H.; Jung C.S.; Choi D.; Kim Y.; Jeon J.S.; Han D.C.; Noh H.; Cardiac arrest caused by nafamostat mesilate. Kidney Res Clin Pract 2016,35(3),187-189","journal-title":"Kidney Res Clin Pract"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4196\/kjpp.2015.19.3.229","volume":"19","author":"Kang M.W.","year":"2015","unstructured":"Kang M.W.; Song H.J.; Kang S.K.; Kim Y.; Jung S.; Jee S.; Moon J.Y.; Suh K.; Lee S.D.; Jeon B.H.; Kim C.S.; Nafamostat mesylate inhibits TNF-\u03b1-induced vascular endothelial cell dysfunction by inhibiting reactive oxygen species production. Korean J Physiol Pharmacol 2015,19(3),229-234","journal-title":"Korean J Physiol Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","volume":"42","author":"Sham H.L.","year":"1998","unstructured":"Sham H.L.; Kempf D.J.; Molla A.; Marsh K.C.; Kumar G.N.; Chen C.M.; Kati W.; Stewart K.; Lal R.; Hsu A.; Betebenner D.; Korneyeva M.; Vasavanonda S.; McDonald E.; Saldivar A.; Wideburg N.; Chen X.; Niu P.; Park C.; Jayanti V.; Grabowski B.; Granneman G.R.; Sun E.; Japour A.J.; Leonard J.M.; Plattner J.J.; Norbeck D.W.; ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998,42(12),3218-3224","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=54","year":"2000","unstructured":"NDA21-226 NDA21-251 Abbott LaboratoriuesAvailable from: 2000","journal-title":"NDA21-226 NDA21-251"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cegh.2020.07.006","volume":"9","author":"Frediansyah A.","year":"2021","unstructured":"Frediansyah A.; Tiwari R.; Sharun K.; Dhama K.; Harapan H.; Antivirals for COVID-19: A critical review. Clin Epidemiol Glob Health 2021,9,90-98","journal-title":"Clin Epidemiol Glob Health"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/TCRM.S3285","volume":"4","author":"Chandwani A.","year":"2008","unstructured":"Chandwani A.; Shuter J.; Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 2008,4(5),1023-1033","journal-title":"Ther Clin Risk Manag"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1592\/phco.21.17.1352.34419","volume":"21","author":"Mangum E.M.","year":"2001","unstructured":"Mangum E.M.; Graham K.K.; Lopinavir-ritonavir: A new protease inhibitor. Pharmacotherapy 2001,21(11),1352-1363","journal-title":"Pharmacotherapy"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14787210.2021.1823832","volume":"19","author":"Hussain N.","year":"2021","unstructured":"Hussain N.; Yoganathan A.; Hewage S.; Alom S.; Harky A.; The effect of antivirals on COVID-19: A systematic review. Expert Rev Anti Infect Ther 2021,19(4),473-486","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1055\/s-2001-18434","volume":"2001","author":"Ghosh A.K.","year":"2001","unstructured":"Ghosh A.K.; Bilcer G.; Schiltz G.; Syntheses of FDA approved HIV protease inhibitors. Synthesis 2001,2001(15),2203-2229","journal-title":"Synthesis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1021\/op990202j","volume":"4","author":"Stoner E.J.","year":"2000","unstructured":"Stoner E.J.; Cooper A.J.; Dickman D.A.; Kolaczkowski L.; Lallaman J.E.; Liu J.H.; Oliver-Shaffer P.A.; Patel K.M.; Paterson J.B.; Plata D.J.; Riley D.A.; Sham H.L.; Stengel P.J.; Tien J.H.J.; Synthesis of HIV protease inhibitor ABT-378 (Lopinavir). Org Process Res Dev 2000,4(4),264-269","journal-title":"Org Process Res Dev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1021\/op980214p","volume":"3","author":"Stoner E.J.","year":"1999","unstructured":"Stoner E.J.; Stengel P.J.; Cooper A.J.; Synthesis of ABT-378, an HIV protease inhibitor candidate: avoiding the use of carbodiimides in a difficult peptide coupling. Org Process Res Dev 1999,3(2),145-148","journal-title":"Org Process Res Dev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"9124","DOI":"10.3390\/ijms22179124","volume":"22","author":"Ahmad B.","year":"2021","unstructured":"Ahmad B.; Batool M.; Ain Q.; Kim M.S.; Choi S.; Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations. Int J Mol Sci 2021,22(17),9124","journal-title":"Int J Mol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"Owen D.R.","year":"2021","unstructured":"Owen D.R.; Allerton C.M.N.; Anderson A.S.; Aschenbrenner L.; Avery M.; Berritt S.; Boras B.; Cardin R.D.; Carlo A.; Coffman K.J.; Dantonio A.; Di L.; Eng H.; Ferre R.; Gajiwala K.S.; Gibson S.A.; Greasley S.E.; Hurst B.L.; Kadar E.P.; Kalgutkar A.S.; Lee J.C.; Lee J.; Liu W.; Mason S.W.; Noell S.; Novak J.J.; Obach R.S.; Ogilvie K.; Patel N.C.; Pettersson M.; Rai D.K.; Reese M.R.; Sammons M.F.; Sathish J.G.; Singh R.S.P.; Steppan C.M.; Stewart A.E.; Tuttle J.B.; Updyke L.; Verhoest P.R.; Wei L.; Yang Q.; Zhu Y.; An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science 2021,374(6575),1586-1593","journal-title":"Science"},{"key":"ref=64","year":"2021","unstructured":"Emergency Use Authorization 105. Pfizer Inc Available from: 2021","journal-title":"Pfizer Inc"},{"key":"ref=65","year":"2021","unstructured":"FDA news release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. Available from: 2021"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1016\/j.bmc.2007.09.010","volume":"15","author":"Ghosh A.K.","year":"2007","unstructured":"Ghosh A.K.; Dawson Z.L.; Mitsuya H.; Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem 2007,15(24),7576-7580","journal-title":"Bioorg Med Chem"},{"key":"ref=67","year":"2006","unstructured":"Drugscom Prezista FDA Approval HistoryAvailable from: 2006","journal-title":"Drugscom"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"104826","DOI":"10.1016\/j.phrs.2020.104826","volume":"157","author":"Riva A.","year":"2020","unstructured":"Riva A.; Conti F.; Bernacchia D.; Pezzati L.; Sollima S.; Merli S.; Siano M.; Lupo A.; Rusconi S.; Cattaneo D.; Gervasoni C.; Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res 2020,157,104826","journal-title":"Pharmacol Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e00825","DOI":"10.1128\/AAC.00825-20","volume":"64","author":"Fintelman-Rodrigues N.","year":"2020","unstructured":"Fintelman-Rodrigues N.; Sacramento C.Q.; Ribeiro Lima C.; Souza da Silva F.; Ferreira A.C.; Mattos M.; de Freitas C.S.; Cardoso S.V.; da Silva G.D.S.; Temerozo J.R.; Miranda M.D.; Matos A.R.; Bozza F.A.; Carels N.; Alves C.R.; Siqueira M.M.; Bozza P.T.; Souza T.M.L.; Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production. Antimicrob Agents Chemother 2020,64(10),e00825-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1128\/AAC.00055-12","volume":"56","author":"Davis D.A.","year":"2012","unstructured":"Davis D.A.; Soule E.E.; Davidoff K.S.; Daniels S.I.; Naiman N.E.; Yarchoan R.; Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing. Antimicrob Agents Chemother 2012,56(7),3620-3628","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"Eastman R.T.","year":"2020","unstructured":"Eastman R.T.; Roth J.S.; Brimacombe K.R.; Simeonov A.; Shen M.; Patnaik S.; Hall M.D.; Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 2020,6(5),672-683","journal-title":"ACS Cent Sci"},{"key":"ref=72","year":"2020","unstructured":"Gilead Sciences Development of RemdesivirAvailable from: 2020","journal-title":"Gilead Sciences"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"Brown A.J.","year":"2019","unstructured":"Brown A.J.; Won J.J.; Graham R.L.; Dinnon K.H.; Sims A.C.; Feng J.Y.; Cihlar T.; Denison M.R.; Baric R.S.; Sheahan T.P.; Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res 2019,169(6),104541","journal-title":"Antiviral Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","volume":"34","author":"Al-Tawfiq J.A.","year":"2020","unstructured":"Al-Tawfiq J.A.; Al-Homoud A.H.; Memish Z.A.; Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020,34,101615","journal-title":"Travel Med Infect Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"Agostini M.L.","year":"2018","unstructured":"Agostini M.L.; Andres E.L.; Sims A.C.; Graham R.L.; Sheahan T.P.; Lu X.; Smith E.C.; Case J.B.; Feng J.Y.; Jordan R.; Ray A.S.; Cihlar T.; Siegel D.; Mackman R.L.; Clarke M.O.; Baric R.S.; Denison M.R.; Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018,9(2),e00221-18","journal-title":"MBio"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1055\/s-0040-1707386","volume":"52","author":"Al Bujuq N.","year":"2020","unstructured":"Al Bujuq N.; Methods of synthesis of remdesivir, favipiravir, hydroxychloroquine, and chloroquine: four small molecules repurposed for clinical trials during the covid-19 pandemic. Synthesis 2020,52(24),3735-3750","journal-title":"Synthesis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1134\/S1068162021030183","volume":"47","author":"Zarenezhad E.","year":"2021","unstructured":"Zarenezhad E.; Behrouz S.; Farjam M.; Rad M.N.S.; A mini review on discovery and synthesis of remdesivir as an effective and promising drug against COVID-19. Russ J Bioorganic Chem 2021,47(3),609-621","journal-title":"Russ J Bioorganic Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"Siegel D.","year":"2017","unstructured":"Siegel D.; Hui H.C.; Doerffler E.; Clarke M.O.; Chun K.; Zhang L.; Neville S.; Carra E.; Lew W.; Ross B.; Wang Q.; Wolfe L.; Jordan R.; Soloveva V.; Knox J.; Perry J.; Perron M.; Stray K.M.; Barauskas O.; Feng J.Y.; Xu Y.; Lee G.; Rheingold A.L.; Ray A.S.; Bannister R.; Strickley R.; Swaminathan S.; Lee W.A.; Bavari S.; Cihlar T.; Lo M.K.; Warren T.K.; Mackman R.L.; Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine c-nucleoside (GS-5734) for the treatment of ebola and emerging viruses. J Med Chem 2017,60(5),1648-1661","journal-title":"J Med Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.20959\/wjpps20208-16808","volume":"9","author":"Khanal P.","year":"2020","unstructured":"Khanal P.; Remdesivir for COVID-19 treatment: Mechanism of action, synthesis, and clinical trials. World J Pharm Pharm Sci 2020,9,1062-1068","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","volume":"55","author":"Ko W.C.","year":"2020","unstructured":"Ko W.C.; Rolain J.M.; Lee N.Y.; Chen P.L.; Huang C.T.; Lee P.I.; Hsueh P.R.; Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 2020,55(4),105933","journal-title":"Int J Antimicrob Agents"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"Jayk Bernal A.","year":"2022","unstructured":"Jayk Bernal A.; Gomes da Silva M.M.; Musungaie D.B.; Kovalchuk E.; Gonzalez A.; Delos Reyes V.; Mart\u00edn-Quir\u00f3s A.; Caraco Y.; Williams-Diaz A.; Brown M.L.; Du J.; Pedley A.; Assaid C.; Strizki J.; Grobler J.A.; Shamsuddin H.H.; Tipping R.; Wan H.; Paschke A.; Butterton J.R.; Johnson M.G.; De Anda C.; Molnupiravirfor oral treatment of COVID-19 in non-hospitalized patients. N Engl J Med 2022,386(6),509-520","journal-title":"N Engl J Med"},{"key":"ref=82","year":"2021","unstructured":"FDA news release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19. Available from: 2021"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1021\/acsomega.1c00772","volume":"6","author":"Ahlqvist G.P.","year":"2021","unstructured":"Ahlqvist G.P.; McGeough C.P.; Senanayake C.; Armstrong J.D.; Yadaw A.; Roy S.; Ahmad S.; Snead D.R.; Jamison T.F.; Progress toward a large-scale synthesis of molnupiravir(MK-4482, EIDD-2801) from cytidine. ACS Omega 2021,6(15),10396-10402","journal-title":"ACS Omega"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jama.2019.20225","volume":"323","author":"Hampton T.","year":"2020","unstructured":"Hampton T.; New flu antiviral candidate may thwart drug resistance. JAMA-. JAMA 2020,323(1),17","journal-title":"JAMA"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"Shiraki K.","year":"2020","unstructured":"Shiraki K.; Daikoku T.; Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 2020,209,107512","journal-title":"Pharmacol Ther"},{"key":"ref=86","year":"2017","unstructured":"L Avigan\u00ae (Favipiravir) Tablets Prescribing Information Taisho Toyama Pharmaceutical CoAvailable from: 2017","journal-title":"L Avigan\u00ae (Favipiravir) Tablets Prescribing Information"},{"key":"ref=87","author":"Rizzardini G.","year":"2020","unstructured":"Rizzardini G.;  Covid-19 clinical study to evaluate the performance and safety of favipiravir in covid-19 Clinicaltrialsgov Available from: 2020","journal-title":"Covid-19 clinical study to evaluate the performance and safety of favipiravir in covid-19 Clinicaltrialsgov"},{"key":"ref=88","year":"2020","unstructured":"Russia approves first covid-19 prescription drug for sale in pharmacies. Reuters Staf Available from: 2020","journal-title":"Reuters Staf"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/cpt.2251","volume":"111","author":"Ueda M.","year":"2022","unstructured":"Ueda M.; Tanimoto T.; Murayama A.; Ozaki A.; Kami M.; Japan\u2019s drug regulation during the COVID-19 pandemic: lessons from a case study of favipiravir. Clin Pharmacol Ther 2022,111(3),545-547","journal-title":"Clin Pharmacol Ther"},{"key":"ref=90","author":"Pulla P.","year":"2020","unstructured":"Pulla P.; Is favipiravir good for COVID-19? clinical trial says no, press release says yes. Sciencethewirein Available from: 2020","journal-title":"Sciencethewirein"},{"key":"ref=91","author":"Furuta Y.","year":"2000","unstructured":"Furuta Y.; Egawa H.;  Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both Available from: 2000","journal-title":"Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s11696-017-0208-6","volume":"71","author":"Liu F.L.","year":"2017","unstructured":"Liu F.L.; Li C.Q.; Xiang H.Y.; Feng S.; A practical and step-economic route to Favipiravir. Chem Pap 2017,71(11),2153-2158","journal-title":"Chem Pap"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s11696-018-0654-9","volume":"73","author":"Guo Q.","year":"2019","unstructured":"Guo Q.; Xu M.; Guo S.; Zhu F.; Xie Y.; Shen J.; The complete synthesis of favipiravir from 2-aminopyrazine. Chem Pap 2019,73(5),1043-1051","journal-title":"Chem Pap"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Furuta Y.","year":"2017","unstructured":"Furuta Y.; Komeno T.; Nakamura T.; Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci 2017,93(7),449-463","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=95","volume":"35","author":"Lau J.","year":"2002","unstructured":"Lau J.; The story of ribavirin. Hepcassoc Available from: 2002,35(5)","journal-title":"Hepcassoc"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1126\/science.177.4050.705","volume":"177","author":"Sidwell R. W.","year":"1972","unstructured":"Sidwell R. W.; Huffman J. H.; Khare G. P.; Allen L. B.; Witkowski J. T.; Robins R. K.; Broad-spectrum antiviral activity of virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972,177,705-706","journal-title":"Science"},{"key":"ref=97","year":"2004","unstructured":"Drugscom Ribasphere FDA Approval HistoryAvailable from: 2004","journal-title":"Drugscom"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","volume":"31","author":"Chen F.","year":"2004","unstructured":"Chen F.; Chan K.H.; Jiang Y.; Kao R.Y.T.; Lu H.T.; Fan K.W.; Cheng V.C.C.; Tsui W.H.W.; Hung I.F.N.; Lee T.S.W.; Guan Y.; Peiris J.S.M.; Yuen K.Y.; In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004,31(1),69-75","journal-title":"J Clin Virol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","volume":"326","author":"Morgenstern B.","year":"2005","unstructured":"Morgenstern B.; Michaelis M.; Baer P.C.; Doerr H.W.; Cinatl J.; Jr Ribavirin and interferon-\u03b2 synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005,326(4),905-908","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/nm.3362","volume":"19","author":"Falzarano D.","year":"2013","unstructured":"Falzarano D.; de Wit E.; Rasmussen A.L.; Feldmann F.; Okumura A.; Scott D.P.; Brining D.; Bushmaker T.; Martellaro C.; Baseler L.; Benecke A.G.; Katze M.G.; Munster V.J.; Feldmann H.; Treatment with interferon-\u03b12b and ribavirin improves outcome in MERS-CoV\u2013infected rhesus macaques. Nat Med 2013,19(10),1313-1317","journal-title":"Nat Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ijid.2021.01.055","volume":"104","author":"Li H.","year":"2021","unstructured":"Li H.; Xiong N.; Li C.; Gong Y.; Liu L.; Yang H.; Tan X.; Jiang N.; Zong Q.; Wang J.; Lu Z.; Yin X.; Efficacy of ribavirin and interferon-\u03b1 therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study. Int J Infect Dis 2021,104,641-648","journal-title":"Int J Infect Dis"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"106114","DOI":"10.1016\/j.ijantimicag.2020.106114","volume":"56","author":"Tong S.","year":"2020","unstructured":"Tong S.; Su Y.; Yu Y.; Wu C.; Chen J.; Wang S.; Jiang J.; Ribavirin therapy for severe COVID-19: A retrospective cohort study. Int J Antimicrob Agents 2020,56(3),106114","journal-title":"Int J Antimicrob Agents"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1021\/jm00281a014","volume":"15","author":"Witkowski J.T.","year":"1972","unstructured":"Witkowski J.T.; Robins R.K.; Sidwell R.W.; Simon L.N.; Design, synthesis, and broad spectrum antiviral activity of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972,15(11),1150-1154","journal-title":"J Med Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"46094","DOI":"10.1074\/jbc.C100349200","volume":"276","author":"Maag D.","year":"2001","unstructured":"Maag D.; Castro C.; Hong Z.; Cameron C.E.; Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001,276(49),46094-46098","journal-title":"J Biol Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1073\/pnas.111085598","volume":"98","author":"Crotty S.","year":"2001","unstructured":"Crotty S.; Cameron C.E.; Andino R.; RNA virus error catastrophe: Direct molecular test by using ribavirin. Proc Natl Acad Sci 2001,98(12),6895-6900","journal-title":"Proc Natl Acad Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0042-6822(03)00152-1","volume":"310","author":"Zhou S.","year":"2003","unstructured":"Zhou S.; Liu R.; Baroudy B.M.; Malcolm B.A.; Reyes G.R.; The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003,310(2),333-342","journal-title":"Virology"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1186\/s12879-020-05698-w","volume":"20","author":"Nojomi M.","year":"2020","unstructured":"Nojomi M.; Yassin Z.; Keyvani H.; Makiani M.J.; Roham M.; Laali A.; Dehghan N.; Navaei M.; Ranjbar M.; Effect of Arbidol (Umifenovir) on COVID-19: A randomized controlled trial. BMC Infect Dis 2020,20(1),954","journal-title":"BMC Infect Dis"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"699949","DOI":"10.3389\/fphar.2021.699949","volume":"12","author":"Liu D.","year":"2021","unstructured":"Liu D.; Zeng X.; Ding Z.; Lv F.; Mehta J.L.; Wang X.; Adverse cardiovascular effects of anti-COVID-19 drugs. Front Pharmacol 2021,12,699949","journal-title":"Front Pharmacol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.eclinm.2021.101169","volume":"41","author":"Zhuravel S.V.","year":"2021","unstructured":"Zhuravel S.V.; Khmelnitskiy O.K.; Burlaka O.O.; Gritsan A.I.; Goloshchekin B.M.; Kim S.; Hong K.Y.; Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine 2021,41,101169","journal-title":"EClinicalMedicine"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"Cao B.","year":"2020","unstructured":"Cao B.; Wang Y.; Wen D.; Liu W.; Wang J.; Fan G.; Ruan L.; Song B.; Cai Y.; Wei M.; Li X.; Xia J.; Chen N.; Xiang J.; Yu T.; Bai T.; Xie X.; Zhang L.; Li C.; Yuan Y.; Chen H.; Li H.; Huang H.; Tu S.; Gong F.; Liu Y.; Wei Y.; Dong C.; Zhou F.; Gu X.; Xu J.; Liu Z.; Zhang Y.; Li H.; Shang L.; Wang K.; Li K.; Zhou X.; Dong X.; Qu Z.; Lu S.; Hu X.; Ruan S.; Luo S.; Wu J.; Peng L.; Cheng F.; Pan L.; Zou J.; Jia C.; Wang J.; Liu X.; Wang S.; Wu X.; Ge Q.; He J.; Zhan H.; Qiu F.; Guo L.; Huang C.; Jaki T.; Hayden F.G.; Horby P.W.; Zhang D.; Wang C.; A trial of lopinavir\u2013ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020,382(19),1787-1799","journal-title":"N Engl J Med"},{"key":"ref=111","year":"2022","unstructured":"Pfizer shares in vitro efficacy of novel covid-19 oral treatment against omicron variant. Available from: 2022"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"21508","DOI":"10.1038\/s41598-020-78697-1","volume":"10","author":"Ayg\u00fcn \u0130.","year":"2020","unstructured":"Ayg\u00fcn \u0130.; Kaya M.; Alhajj R.; Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep 2020,10(1),21508","journal-title":"Sci Rep"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"110532","DOI":"10.1016\/j.biopha.2020.110532","volume":"130","author":"Fan Q.","year":"2020","unstructured":"Fan Q.; Zhang B.; Ma J.; Zhang S.; Safety profile of the antiviral drug remdesivir: An update. Biomed Pharmacother 2020,130,110532","journal-title":"Biomed Pharmacother"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2100044","volume":"1","author":"Arribas J.R.","year":"2021","unstructured":"Arribas J.R.; Bhagani S.; Lobo S.M.; Khaertynova I.; Mateu L.; Fishchuk R.; Park W.Y.; Hussein K.; Kim S.W.; Ghosn J.; Brown M.L.; Zhang Y.; Gao W.; Assaid C.; Grobler J.A.; Strizki J.; Vesnesky M.; Paschke A.; Butterton J.R.; De Anda C.; Randomized trial of molnupiravir or placebo in patients hospitalized with covid-19. NEJM Evid 2021,1(2),1-13","journal-title":"NEJM Evid"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.2147\/IDR.S287934","volume":"13","author":"Kaur R.J.","year":"2020","unstructured":"Kaur R.J.; Charan J.; Dutta S.; Sharma P.; Bhardwaj P.; Sharma P.; Lugova H.; Krishnapillai A.; Islam S.; Haque M.; Misra S.; Favipiravir use in COVID-19: Analysis of suspected adverse drug events reported in the who database. Infect Drug Resist 2020,13,4427-4438","journal-title":"Infect Drug Resist"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"e22379","DOI":"10.1097\/MD.0000000000022379","volume":"99","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Li W.; Jiang Z.; Xi X.; Zhu Y.; Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19). Medicine 2020,99(38),e22379","journal-title":"Medicine"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230302113110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/214258\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230302113110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T15:38:26Z","timestamp":1691768306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/214258\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":116,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201024666230302113110","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}